Lupus & antiphospholipid syndrome
Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study
An erratum to this article was published (Arthritis Rheumatol, Aug 2023 ↗)
Authors' conclusion
In SLE patients with active disease receiving standard of care, mSRI attainment predicts favorable outcomes over long-term follow-up
Study context
- Population
- Systemic lupus erythematosus (SLE) patients with active disease (SLEDAI-2K ≥6) receiving standard of care, large multicentre longitudinal cohortmedian baseline SLEDAI-2K 8
- Participants
- 2,060 patients
- Exposure
- mSRI responders vs nonresponders
- Outcome
- Association of mSRI attainment with long-term clinical outcomes
- Follow-up
- Annually up to 5 years
Methodological detailsmulticentre, longitudinal, up to 5 years of follow-up
- Multicentre
- Longitudinal
- Up to 5 years of follow-up
Main finding
As reported in the abstract
mSRI response attained at 1 year
56%
Observational data: associations, not effects.
Further findings
| Outcome | OR range | P value |
|---|---|---|
| Damage accrual at subsequent years, predicted by mSRI responder status at 1 year | 0.58-0.69 | P < 0.05 for damage accrual ORs at all time points |
Damage accrual at subsequent years, predicted by mSRI responder status at 1 year
- mSRI responder status at 1 year predicted clinical benefit at subsequent years across most outcomes
Original publication
Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study. Arthritis Rheumatol. Published 16 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →